Last reviewed · How we verify
Fluticasone 250/formoterol 10
Fluticasone 250/formoterol 10 is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by Research in Real-Life Ltd. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: Flutiform 250.
Fluticasone/formoterol is an inhaled combination of a corticosteroid and a long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.
Fluticasone/formoterol is an inhaled combination of a corticosteroid and a long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Fluticasone 250/formoterol 10 |
|---|---|
| Also known as | Flutiform 250 |
| Sponsor | Research in Real-Life Ltd |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and sustained airway opening. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Nervousness
Key clinical trials
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) (PHASE3)
- Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years (PHASE3)
- Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma (PHASE3)
- A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD (PHASE3)
- Flutiform® Compared With Seretide® in the Treatment of COPD (PHASE2, PHASE3)
- A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down (PHASE4)
- A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone 250/formoterol 10 CI brief — competitive landscape report
- Fluticasone 250/formoterol 10 updates RSS · CI watch RSS
- Research in Real-Life Ltd portfolio CI
Frequently asked questions about Fluticasone 250/formoterol 10
What is Fluticasone 250/formoterol 10?
How does Fluticasone 250/formoterol 10 work?
What is Fluticasone 250/formoterol 10 used for?
Who makes Fluticasone 250/formoterol 10?
Is Fluticasone 250/formoterol 10 also known as anything else?
What drug class is Fluticasone 250/formoterol 10 in?
What development phase is Fluticasone 250/formoterol 10 in?
What are the side effects of Fluticasone 250/formoterol 10?
What does Fluticasone 250/formoterol 10 target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination drugs
- Target: All drugs targeting Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)
- Manufacturer: Research in Real-Life Ltd — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Also known as: Flutiform 250
- Compare: Fluticasone 250/formoterol 10 vs similar drugs
- Pricing: Fluticasone 250/formoterol 10 cost, discount & access